| Summary: | In January 2022, we published an evolving rapid review, meta-analysis, and data visualization that compared the risk of reinfection in adults with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to the risk of infection in adults without a prior infection. We found that prior infection with the Alpha variant or the wild-type SARS-CoV-2 virus reduced the risk of another infection by 80-97 percent (pooled estimate 87%; 95% confidence interval [CI] 84-90%) compared with uninfected individuals in studies with a median followup of 8 months (range 4 to 13 months). Protection remained above 80 percent for at least 7 months. Our original review, published in March 2021,2 described the antibody response after infection with the SARS-CoV-2 virus, but found little information on the duration of the response beyond 6 months or on antibody formation in asymptomatic patients or in individuals who are immunocompromised
|
|---|